Focus Universal 3Q 2026: Revenue $802.43K — 10-Q Summary

Focus Universal Inc. (NASDAQ: FCUV) shares rose sharply after the company announced its Deterministic AI Forms Auto-Populate Engine for autonomous document processing. The article says FCUV was up 12.13 (+644.95%) to $14.01 with a morning high of $17.59 on volume of 57 million. The platform is described as extracting, validating, and populating business forms using deterministic logic.

Focus Universal Inc. (FCUV) shares rose more than 500% on Friday after the company announced the launch of its Deterministic AI Forms Auto-Populate Engine for enterprise document workflows. The stock was trading around $12.90 on Nasdaq, up about 585% from the prior close, after opening at $10.22 and reaching $17.59 intraday.

Cumberland Pharmaceuticals (CPIX) reported Q3 earnings, including a $108M net funding estimate from a transaction, a $1.50 special dividend, and share repurchase plans. The company projects cash to fund operations for over five years. Cumberland is preparing a new drug application for ifetroban to treat Duchenne muscular dystrophy, with FDA rolling review granted. The company also discussed other clinical programs and retained majority ownership of Cumberland Emerging Technologies.

Grocery Outlet (GO) reported Q3 adjusted earnings of $0.16 per share, down from $0.21 a year earlier, with adjusted EBITDA falling to $59.4 million. The company cited promotional spending, higher supply chain costs, and increased produce shrink for the decline. GO forecasted Q4 comparable-store sales growth of 1.5% to 2.5% and adjusted earnings of $0.11 to $0.14 per share. The company plans to open 20-31 net new stores in 2027, all in existing markets.

Capricor Therapeutics reported a Q3 net loss of $42.7M, widening from $24.6M a year earlier. The company highlighted positive data on Deramiocel, its lead therapy, showing improved upper limb function in patients. Capricor is preparing for a potential launch while resolving a distribution dispute with Nippon Shinyaku. The company has sufficient cash to fund operations for at least 12 months.

Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.